Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound SBM-TFC-1067 Accepted as Abstract Presentation by IMCAS
– Momentum Public Relations – June 16th, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced positive preclinical safety and efficacy data with SBM-TFC-1067 in a 3-D human skin-like model was accepted as an abstract for oral presentation by Sirona’s Chief Scientific Officer, Geraldine Deliencourt-Godefroy, at the IMCAS Asia Conference in Taipei on July 31, 2016.
Sirona has now demonstrated significant skin lightening in a model used by cosmetic scientists and leading cosmetic corporations around the world. In the study, SBM-TFC-1067, was topically applied daily to a MatTek Corps Melanoderm 3-D human skin model for 14 days using 3 different concentrations (0.1, 0.05 and 0.01{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}). Pigmentation was evaluated on days 0, 7, 11, and 14 using a chromameter to measure brightness (L*D65). Total melanin content was quantified after day 14. Results showed a statistically significant difference in surface reflectance with the 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and 0.05{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} concentrations of 1067. There was also a significant reduction of melanin quantity, which translates to visibly lighter skin.
The full abstract can be viewed on the IMCAS website here: http://www.imcas.com/en/attend/imcas-asia-2016/program/session/6150
“This is definitely good news for the millions of individuals around the world with hyperpigmentation or melasma”, said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “This exciting new data shows significant reduction in pigmentation without toxicity in human skin and being accepted as an abstract in the clinical dermatology stream at IMCAS is scientific validation.”
About IMCAS
Since its inception a decade ago, IMCAS has become one of the most important international programs dedicated to skin treatments. IMCAS Asia 2016, will bring together practitioners from across the Asia-Pacific region for informative and engaging exchanges. Over 2000 attendees and 80 exhibiting companies will come together for three days of intense learning in Taipei. Large cosmetic company representatives will also be in attendance to learn about the most innovative advances in the dermatology industry.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
About the Skin Lightening Project
Sirona Biochem’s French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and EU are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.